NCT02747472

GIP Receptor Antagonist Studies in Humans

Involvement of Glucose-dependent Insulinotropic Polypeptide (GIP) in Human Physiology and Pathophysiology - Receptor Antagonist Studies in Humans

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: Male
• Age: 20 Years – 30 Years
• Healthy volunteers: Accepted

Summary

Antagonizing GIP effects during hyperglycaemia in healthy subjects and measurements of insulin secretion.

Detailed description

Aim: To evaluate the GIP receptor antagonizing effect of peptide-based competitive GIP receptor antagonist GIP-A (vs. saline (placebo)) in 10 healthy subjects during 1 hour hyperglycaemic clamps with and without concomitant iv infusion of GIP\[1-42\]. The intention is to establish GIP-A as a tool to eliminate glucose-dependent insulinotropic GIP signalling. The study consists of four experimental days (A-D) with assessment of beta cell function during 12 mM-hyperglycaemic clamps with concomitant infusions of A) GIP\[1-42\], B) GIP-A, C) GIP\[1-42\] + GIP-A, or D) saline (placebo).

Conditions

• Glucose Metabolism

Interventions

Type	Name	Description
DRUG	GIP-A	GIP receptor antagonist
DRUG	GIP(1-42)	GIP receptor agonist
OTHER	Saline	Placebo

Timeline

• Start date: 2016-04-01
• Primary completion: 2016-07-01
• Completion: 2016-07-01
• First posted: 2016-04-21
• Last updated: 2017-04-27

Locations

1 site across 1 country: Denmark